Zealand Pharma steadfastly upholds amylin-based obesity drug strategy
Zealand’s CEO Adam Steensberg said that the company is “exactly where it wants to be” in terms of its partnering and ...
NVO INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Reminds Stockholders of Novo Nordisk A/S to Contact the Firm Today!
NEW YORK, NY / ACCESS Newswire / February 20, 2025 / Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, ...
Scandasia.com16h
Novo Nordisk sues Singapore biotech firm over $1.3 billion acquisition dispute
Novo Nordisk, the Danish pharmaceutical giant, has filed a lawsuit against Singapore-based KBP Biosciences and its founder, ...
Why Novo Nordisk Is A Strong Buy Despite Market Concerns
Novo Nordisk thrives despite competition and explore its breakthrough amycretin study. Read here to know why we rate NVO ...